# Verteporfin

## Visudyne inj 15mg/vial

##### 臨採

| TAH Drug Code      | IVIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Subfoveal choroidal neovascularization: Treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Adult: 6 mg/m2 by infusion over 10 min, followed by activation using a laser tuned to a wavelength of 689 nm 15 min after the start of the infusion. Recommended light dose is 50J/cm2, given over 83 sec. Repeat every 3 months for recurrent choroidal neovascular leakage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Known hypersensitivity to verteporfin or any component of the formulation; porphyria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | >10%: Local: Injection site reactions (including injection site discoloration, edema, extravasation, hemorrhage, inflammation, pain, and rash) Ocular: Blurred vision, flashes of light, visual acuity decreased, visual field defects (including scotoma) 1% to 10%: Cardiovascular: Atrial fibrillation, hypertension, peripheral vascular disorder, varicose veins Central nervous system: Fever, hypoesthesia, sleep disturbance, vertigo Dermatologic: Eczema, photosensitivity Gastrointestinal: Constipation, gastrointestinal cancers, nausea Genitourinary: Prostatic disorder Hematologic: Anemia, leukocytosis, leukopenia Hepatic: Liver function tests increased Neuromuscular & skeletal: Arthralgia, arthrosis, back pain (primarily during infusion), myasthenia, weakness Ocular: Diplopia, lacrimation disorder Treatment site: Blepharitis, cataracts, conjunctivitis/conjunctival injection, dry eyes, ocular itching, severe vision loss with or without subretinal/retinal or vitreous hemorrhage (decrease in 4 lines or more within 7 days of treatment [1% to 5%]) Otic: Hearing loss Renal: Albuminuria, creatinine increased Respiratory: Cough, pharyngitis, pneumonia Miscellaneous: Flu-like syndrome |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

